MeSH D013964 - thyroid neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Doxorubicin | Doxorubicin |  | 1995-07-28 |  |  |
| Levothyroxine | Levothyroxine |  | 2020-10-28 |  |  | |
| Liothyronine | Liothyronine |  | 2018-10-26 |  |  | |
| Doxorubicin | Myocet (previously Myocet) |  | 2000-07-13 |  |  | |
| Sorafenib | Sorafenib |  | 2020-11-12 |  |  | |
| Mylan | Doxorubicin | Doxorubicin |  | 2011-10-28 |  |  |
| Levothyroxine | Ermeza | 2035-02-27 | 2022-04-29 |  |  | |
| Levothyroxine | Levothyroxine |  | 2002-06-05 |  |  | |
| Liothyronine | Liothyronine |  | 2009-07-14 |  |  | |
| Sorafenib | Sorafenib |  | 2020-09-10 |  |  | |
| Lupin Research | Levothyroxine | Levothyroxine |  | 2019-01-18 |  |  |
| Doxorubicin | Doxorubicin |  | 2024-07-16 |  |  | |
| AbbVie | Levothyroxine | Synthroid |  | 2002-07-24 | $767 M | Y2021 |
| Sanofi | Vandetanib | Caprelsa | 2022-02-06 | 2011-04-06 |  |  |
| Thyrotropin alfa | Thyrogen |  | 1998-11-30 |  |  | |
| King Pharmaceuticals | Liothyronine | Cytomel |  | 1982-01-01 |  |  |
| Levothyroxine | Levoxyl | 2022-02-15 | 2001-05-25 |  |  | |
| Genus Lifesciences | Levothyroxine | Levolet | 2038-03-23 | 2003-06-06 |  |  |
| Bayer | Sorafenib | Nexavar | 2023-02-11 | 2005-12-20 |  |  |
| Pfizer | Doxorubicin | Adriamycin |  | 1991-01-30 |  |  |
| Doxorubicin | Doxorubicin |  | 1982-01-01 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
82%36/44
Phase 2
12%13/110
Phase 3
69%20/29
Approved: 14Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use